Stocktoria
Sarepta Therapeutics, Inc. SRPT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1997-06-04
Sarepta Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.2B | $933.0M | $701.9M |
| SG&A expense | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M |
| Interest expense | -$38.1M | -$18.4M | -$22.0M | -$53.2M | $63.5M |
| Income tax | $11.2M | $25.5M | $15.9M | $13.5M | -$168,000 |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M |
| EPS (diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M |
| Cash & equivalents | $801.3M | $1.1B | $428.4M | $966.8M | $2.1B |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M |
| Total assets | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B |
| Total liabilities | $2.2B | $2.4B | $2.4B | $2.7B | $2.2B |
| Shareholders' equity | $1.1B | $1.5B | $859.3M | $384.9M | $928.0M |
Source: SEC EDGAR filings · CIK 0000873303 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.